KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 78 filers reported holding KINNATE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,261,272 | -53.8% | 2,329,480 | 0.0% | 0.99% | -58.8% |
| Q2 2023 | $7,058,324 | -51.5% | 2,329,480 | 0.0% | 2.40% | -60.5% |
| Q1 2023 | $14,559,250 | +2.5% | 2,329,480 | 0.0% | 6.08% | +7.5% |
| Q4 2022 | $14,209,828 | -55.3% | 2,329,480 | -12.5% | 5.65% | -45.0% |
| Q3 2022 | $31,810,000 | -16.1% | 2,661,888 | -11.5% | 10.27% | -19.7% |
| Q2 2022 | $37,934,000 | +12.0% | 3,008,243 | 0.0% | 12.80% | +32.3% |
| Q1 2022 | $33,873,000 | -36.5% | 3,008,243 | 0.0% | 9.67% | -31.1% |
| Q4 2021 | $53,306,000 | – | 3,008,243 | – | 14.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |